Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 3/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.49 |
| ▸ | ACP1 | P24666 | 3/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 2/20 | 0.42 |
| ▸ | MMP13 | P45452 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4351250 | 1.00 | ADAMTS5 (0.51) | ADAMTS5ALOX5PTPN1ACP1PTPN2 | |
| SCHEMBL4355527 | 0.91 | ALOX5 (0.51) | ADAMTS5ALOX5PTPN1ACP1PTPN2 | |
| SCHEMBL4355526 | 0.91 | ALOX5 (0.51) | ADAMTS5ALOX5PTPN1ACP1PTPN2 | |
| SCHEMBL4354740 | 0.90 | PTPN1 (0.51) | ADAMTS5PTPN1ACP1AKR1B1MMP3 | |
| SCHEMBL4354737 | 0.90 | PTPN1 (0.51) | ADAMTS5PTPN1ACP1AKR1B1MMP3 | |
| SCHEMBL4350290 | 0.87 | ALOX5 (0.52) | ADAMTS5ALOX5PTPN1ACP1AKR1B1 | |
| SCHEMBL4350295 | 0.87 | ALOX5 (0.52) | ADAMTS5ALOX5PTPN1ACP1AKR1B1 | |
| SCHEMBL4354245 | 0.84 | PTPN1 (0.45) | ALOX5PTPN1ACP1PTPN2EPHX2 | |
| SCHEMBL4354241 | 0.84 | PTPN1 (0.45) | ALOX5PTPN1ACP1PTPN2EPHX2 | |
| SCHEMBL4363199 | 0.80 | ALOX5 (0.44) | ALOX5AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1890695-B1 | USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS | GRUENENTHAL GMBH (DE) | 2013-02-20 | — | — | EP | claimed |
| US-20090215758-A1 | Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs | GRUENENTHAL GMBH (DE) | 2009-08-27 | — | — | US | claimed |
| US-20090215758-A1 | Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs | GRUENENTHAL GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215758-A1 | Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs | ABCB1, ABCG2, SLC5A2 | ADAMTS5 145/4885ALOX5 2623/4885PTPN1 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.